The JNK Signaling Pathway in Inflammatory Skin Disorders and Cancer

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2020 Apr 8

PMID 32252279

Citations 109

Authors

Manel B Hammouda

Amy E Ford

Yuan Liu

Jennifer Y Zhang

Affiliations

Soon will be listed here.

Abstract

The c-Jun N-terminal kinases (JNKs), with its members JNK1, JNK2, and JNK3, is a subfamily of (MAPK) mitogen-activated protein kinases. JNK signaling regulates a wide range of cellular processes, including cell proliferation, differentiation, survival, apoptosis, and inflammation. Dysregulation of JNK pathway is associated with a wide range of immune disorders and cancer. Our objective is to provide a review of JNK proteins and their upstream regulators and downstream effector molecules in common skin disorders, including psoriasis, dermal fibrosis, scleroderma, basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma.

Citing Articles

Resveratrol contributes to NK cell-mediated breast cancer cytotoxicity by upregulating ULBP2 through miR-17-5p downmodulation and activation of MINK1/JNK/c-Jun signaling.

Ding B, Li J, Yan J, Jiang C, Qian L, Pan J Front Immunol. 2025; 16:1515605.

PMID: 39963142 PMC: 11830804. DOI: 10.3389/fimmu.2025.1515605.

Chitosan capped-NLCs enhanced codelivery of gefitinib and simvastatin into MDR HCC: impact of compositions on cell death, JNK3, and Telomerase.

Harisa G, Alzhrani R, Alluhaidan A, Alamri S, Bakheit A, Asiri H Oncol Res. 2025; 33(2):477-492.

PMID: 39866231 PMC: 11754001. DOI: 10.32604/or.2024.053337.

Mechanical stretch-induced IGF2 overexpression in epidermal keratinocytes promotes hypertrophic scar formation through the IGF1R/p-c-Jun axis.

Zhu Y, Chen L, Song B, Cui Z, Chen G, Dou W Int J Biol Sci. 2025; 21(1):109-127.

PMID: 39744430 PMC: 11667814. DOI: 10.7150/ijbs.91661.

Immunomodulatory potential of primary cilia in the skin.

Sun J, Yuan H, Yu Y, Li A, Zhao Z, Tang Y Front Immunol. 2024; 15:1456875.

PMID: 39676858 PMC: 11638010. DOI: 10.3389/fimmu.2024.1456875.

Immunomodulatory activity of metoclopramide HCl on murine macrophages.

Aydemir E Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39673636 DOI: 10.1007/s00210-024-03715-2.

References

Arakaki P, Marques M, Santos M . MMP-1 polymorphism and its relationship to pathological processes. J Biosci. 2009; 34(2):313-20. DOI: 10.1007/s12038-009-0035-1. View

Avouac J, Palumbo K, Tomcik M, Zerr P, Dees C, Horn A . Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis. Arthritis Rheum. 2011; 64(5):1642-52. DOI: 10.1002/art.33501. View

Afonina I, Nuffel E, Baudelet G, Driege Y, Kreike M, Staal J . The paracaspase MALT1 mediates CARD14-induced signaling in keratinocytes. EMBO Rep. 2016; 17(6):914-27. PMC: 5278603. DOI: 10.15252/embr.201642109. View

Jin Y, Park I, Hong I, Byun H, Choi J, Kim Y . Fibronectin and vitronectin induce AP-1-mediated matrix metalloproteinase-9 expression through integrin α(5)β(1)/α(v)β(3)-dependent Akt, ERK and JNK signaling pathways in human umbilical vein endothelial cells. Cell Signal. 2010; 23(1):125-34. DOI: 10.1016/j.cellsig.2010.08.012. View

Zhou B, Zhu H, Luo H, Gao S, Dai X, Li Y . MicroRNA-202-3p regulates scleroderma fibrosis by targeting matrix metalloproteinase 1. Biomed Pharmacother. 2017; 87:412-418. DOI: 10.1016/j.biopha.2016.12.080. View

Riesenberg S, Groetchen A, Siddaway R, Bald T, Reinhardt J, Smorra D . MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. Nat Commun. 2015; 6:8755. PMC: 4659938. DOI: 10.1038/ncomms9755. View

Han M, Jung D, Morel C, Lakhani S, Kim J, Flavell R . JNK expression by macrophages promotes obesity-induced insulin resistance and inflammation. Science. 2012; 339(6116):218-22. PMC: 3835653. DOI: 10.1126/science.1227568. View

Loesche M, Farahi K, Capone K, Fakharzadeh S, Blauvelt A, Callis Duffin K . Longitudinal Study of the Psoriasis-Associated Skin Microbiome during Therapy with Ustekinumab in a Randomized Phase 3b Clinical Trial. J Invest Dermatol. 2018; 138(9):1973-1981. DOI: 10.1016/j.jid.2018.03.1501. View

Singh S, Pradhan D, Puri P, Ramesh V, Aggarwal S, Nayek A . Genomic alterations driving psoriasis pathogenesis. Gene. 2018; 683:61-71. DOI: 10.1016/j.gene.2018.09.042. View

10.

Liang J, Chen P, Li C, Li D, Wang J, Xue R . IL-22 Down-Regulates Cx43 Expression and Decreases Gap Junctional Intercellular Communication by Activating the JNK Pathway in Psoriasis. J Invest Dermatol. 2018; 139(2):400-411. DOI: 10.1016/j.jid.2018.07.032. View

11.

VanHooser A, Goodrich D, Brinkley B, Tan T . Cell cycle regulation of c-Jun N-terminal kinase activity at the centrosomes. Biochem Biophys Res Commun. 2001; 289(1):173-80. DOI: 10.1006/bbrc.2001.5948. View

12.

Carboni S, Boschert U, Gaillard P, Gotteland J, Gillon J, Vitte P . AS601245, a c-Jun NH2-terminal kinase (JNK) inhibitor, reduces axon/dendrite damage and cognitive deficits after global cerebral ischaemia in gerbils. Br J Pharmacol. 2007; 153(1):157-63. PMC: 2199388. DOI: 10.1038/sj.bjp.0707574. View

13.

Gazon H, Barbeau B, Mesnard J, Peloponese Jr J . Hijacking of the AP-1 Signaling Pathway during Development of ATL. Front Microbiol. 2018; 8:2686. PMC: 5775265. DOI: 10.3389/fmicb.2017.02686. View

14.

Seki E, Brenner D, Karin M . A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology. 2012; 143(2):307-20. PMC: 3523093. DOI: 10.1053/j.gastro.2012.06.004. View

15.

Du L, Anderson A, Nguyen K, Ojeda S, Ortiz-Rivera I, Nguyen T . JNK2 Is Required for the Tumorigenic Properties of Melanoma Cells. ACS Chem Biol. 2019; 14(7):1426-1435. PMC: 7181303. DOI: 10.1021/acschembio.9b00083. View

16.

Berwick M . The good, the bad, and the ugly of sunscreens. Clin Pharmacol Ther. 2010; 89(1):31-3. DOI: 10.1038/clpt.2010.227. View

17.

Gilbane A, Denton C, Holmes A . Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells. Arthritis Res Ther. 2013; 15(3):215. PMC: 4060542. DOI: 10.1186/ar4230. View

18.

Annunziato F, Romagnani C, Romagnani S . The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol. 2014; 135(3):626-35. DOI: 10.1016/j.jaci.2014.11.001. View

19.

Bain J, McLauchlan H, Elliott M, Cohen P . The specificities of protein kinase inhibitors: an update. Biochem J. 2003; 371(Pt 1):199-204. PMC: 1223271. DOI: 10.1042/BJ20021535. View

20.

Rincon M, Davis R . Regulation of the immune response by stress-activated protein kinases. Immunol Rev. 2009; 228(1):212-24. DOI: 10.1111/j.1600-065X.2008.00744.x. View